These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33386279)

  • 1. 2-[
    Albano D; Camoni L; Rodella C; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e277-e283. PubMed ID: 33386279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[
    Albano D; Calabrò A; Dondi F; Bertagna F
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399491
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Value of
    Albano D; Camoni L; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
    Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of baseline 2-[
    Albano D; Calabrò A; Dondi F; Bagnasco S; Tucci A; Bertagna F
    Hematol Oncol; 2024 Mar; 42(2):e3266. PubMed ID: 38444261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.
    Albano D; Mazzoletti A; Spallino M; Muzi C; Zilioli VR; Pagani C; Tucci A; Rossetti C; Giubbini R; Bertagna F
    Ann Hematol; 2020 Jun; 99(6):1321-1330. PubMed ID: 32333153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic behavior and prognostic role of pretreatment 18F-FDG PET/CT in gist.
    Albano D; Bosio G; Tomasini D; Bonù M; Giubbini R; Bertagna F
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e207-e215. PubMed ID: 32762133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of baseline
    Dondi F; Albano D; Bellini P; Cerudelli E; Treglia G; Bertagna F
    Clin Imaging; 2023 Feb; 94():71-78. PubMed ID: 36495848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between Baseline [
    Dondi F; Albano D; Bellini P; Camoni L; Treglia G; Bertagna F
    Tomography; 2022 Oct; 8(6):2662-2675. PubMed ID: 36412681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
    Dondi F; Albano D; Bertagna F; Giubbini R
    Nucl Med Rev Cent East Eur; 2022; 25(2):78-84. PubMed ID: 35848529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.